Key Takeaways
- Lilly's Omvoh shows durable 4-year disease clearance in ulcerative colitis.
- 63.5% of patients maintaining clearance sets a new bar for IL-23p19 inhibitors.
- Data strengthens Omvoh's position in a competitive immunology market.
Back
Lilly's Omvoh sustains 64% disease clearance at 4 years in UC
Eli Lilly and Company (NYSE: LLY) announced that its ulcerative colitis drug Omvoh sustained disease clearance in nearly 64 percent of patients over four years, setting a new long-term benchmark for IL-23p19 inhibitors.
"For a progressive disease like ulcerative colitis, that level of durable remission has the potential to change the long-term course of the disease for patients," said Jean-Frédéric Colombel, M.D., director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai.
The new analysis from the LUCENT-3 open-label extension study, presented at Digestive Disease Week, showed 63.5% of patients who achieved disease clearance with Omvoh (mirikizumab-mrkz) at one year maintained it at four years. Disease clearance is a composite endpoint requiring the simultaneous achievement of symptomatic, endoscopic, and histologic remission—a high bar for treatment success.
The positive long-term data reinforces Omvoh's position in the crowded inflammatory bowel disease market and supports Eli Lilly's growing immunology franchise. Lilly, with a market capitalization of over $860 billion, is pursuing further combination studies to solidify its leadership.
Sustained Efficacy Over Four Years
The post-hoc analysis evaluated patients from the LUCENT-2 maintenance study who continued into the LUCENT-3 extension. The results mark the first time an IL-23p19 inhibitor has demonstrated such durable, composite disease clearance over a four-year period in ulcerative colitis. Even when measured by a more stringent definition requiring complete endoscopic normalization, 61.3% of patients who had achieved it at one year maintained it through year four.
In the three-year extension study, patients treated with Omvoh reported only one UC-related hospitalization and no UC-related surgeries. The safety profile remained consistent with previous findings, with 12% of patients reporting a serious adverse event and 7% discontinuing treatment due to an adverse event over the long-term study. The most common reactions included upper respiratory tract infections, injection site reactions, and headache.
Competitive and Future Landscape
The data gives Lilly a strong durability claim in the competitive inflammatory bowel disease space. Other companies are also exploring novel approaches, with recent data from the DUET-UC trial showing a combination therapy from Johnson & Johnson targeting two inflammatory pathways at once also yielded positive results in treatment-resistant patients.
Lilly is also advancing its pipeline, with combination studies of mirikizumab planned with other agents like eltrekibart and zotemtegrast. The company is also investigating the use of its popular incretin-based therapies alongside mirikizumab for IBD patients with obesity.
The four-year data provides strong evidence of Omvoh's long-term efficacy, a key factor for physicians and payers in managing chronic diseases like ulcerative colitis. Investors will watch how these results translate into market share gains against competitors and the progress of Lilly's combination therapy trials.
This article is for informational purposes only and does not constitute investment advice.
[1] Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years[2] Combination therapy could improve outcomes in the most difficult-to-treat patients with inflammatory bowel disease[3] Lilly reports four-year disease clearance data for Omvoh in UC - Investing.com Canada
